Wednesday, September 25, 2013 3:55:06 PM
By having ESI spun out, ESI can now be acquired standalone without the HP. If interested in the ESI technology but not the HP they will not have the added cost of acquisition for something that doesn't fit their needs or the resistance of AEMD against acquisition due to AEMD not wanting to sell the HP technology. I believe the value of ESI can now be determined on it's own merit and not with AEMD as a whole.
This could make the whole company more valuable in the long run having it's technology sectors broken up into different parts while also allowing AEMD to sell ESI if wanted to gain needed funds for trials, costs to gain approval for commercialization, marketing/promotion and manufacturing of the HP.
This could make the whole company more valuable in the long run having it's technology sectors broken up into different parts while also allowing AEMD to sell ESI if wanted to gain needed funds for trials, costs to gain approval for commercialization, marketing/promotion and manufacturing of the HP.
Recent AEMD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:18 PM
- Advancements in Novel Immunotherapeutics in The Oncology Battle • Newsfile • 03/24/2026 02:30:00 PM
- Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review • PR Newswire (US) • 03/24/2026 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 01:15:09 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities • PR Newswire (US) • 03/12/2026 12:01:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th • GlobeNewswire Inc. • 03/06/2026 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:15:32 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 02:54:05 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/18/2026 01:22:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 10:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:15:44 PM
- Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update • PR Newswire (US) • 02/12/2026 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026 • PR Newswire (US) • 02/04/2026 01:01:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/27/2026 09:15:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/27/2026 09:15:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2026 10:15:32 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/16/2026 10:14:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/16/2026 09:15:44 PM
